All In Biotech

Drug Trial Radar · NCT06637254

A Study to Evaluate the Efficacy and Safety of HSK31858 Tablets in Patients with Bronchial Asthma

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Efficacy and Safety of HSK31858 Tablets in Patients with Bronchial Asthma

Last checked: Nov 20, 2026Latest source record: Dec 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 219 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

219

Planned (sponsor's estimate)

Start

Oct 22, 2024

Primary completion

Mar 22, 2026

Study completion Sep 20, 2026

Sponsor

Sponsor type
Industry
First posted
Oct 15, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase II, randomised, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of HSK31858 in patients with bronchial asthma

Conditions

  • Bronchial Asthma

Interventions

  • HSK31858Drug

    HSK31858 is a novel inhibitor of DPP1 developed by Hisco Pharmaceutical and can reduce pulmonary exacerbations over a 48-week treatment period in patients with bronchial asthma

  • PlaceboDrug

    the placebo comparator of study

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The annualized asthma exacerbation rate within 24 weeksTime frame: 24-week treatment period

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.